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Introduction
Human lactoferrin (hLF) is known to be a multifunctional protein 
of the transferrin family. It is a glycoprotein of approximately 80KDa 
and is present in various human secretory fluids including milk, saliva, 
tears and nasal secretions as well as being abundant in neutrophils [1-
4]. The hLf protein includes 703 amino acids as a single polypeptide 
chain that folds into two similar globular lobes—C- and N-terminal 
regions. The structure is maintained by multiple intra-chain disulfide 
bonds and the lobes are connected by a short α-helical region. The 
isoelectric point of hLf is 8.7 and there are two iron binding sites and 5 
potential asparagine-linked glycosylation sites in the molecule [5]. The 
degree of glycosylation of the protein varies with the tissue of expression 
and the metabolic status of the producing cells [6]. Each lactoferrin 
molecule can reversibly bind two ions of iron with high affinity, but 
it may also bind zinc, copper or other metals with lower affinity [7]. 
After combining with iron, it forms a reddish complex. The affinity for 
iron is 300 times higher than that of transferrin, although the amino 
acid sequences are 60% identical [8]. The characteristics of hLF were 
first published in 1984 and the similarities to transferrin were noted [5]. 
The concentration of lactoferrin in human milk is approximately 7 g/L, 
much higher than in milk of non-primate species of mammals.
Human lactoferrin has been demonstrated to have antibacterial, 
antiviral, anti-inflammatory and antioxidant properties [9-16]. It can 
interact with human cells to modulate the inflammatory process and 
innate defense reactions [17]. Lastly, dietary hLF provides an important 
mechanism for efficient iron absorption, especially in the neonate, as 
well as promoting intestinal epithelial cell growth [17].
Researchers have considered using hLF in a wide variety of 
applications due to its bioactivities. Potential applications include 
the prophylactic treatment of inflammatory disease [18,19] and iron 
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deficiency [20]. It has also been proposed for use as a food additive [21] 
to reduce microbial spoilage.
Large-scale production of hLF is necessary to meet the potential 
demand for its many uses. Although several efficient methods have 
been used to purify hLF from breast milk [22-26], its supply is quite 
limited, expensive and there is concern regarding the potential for 
naturally purified hLF to transmit disease vectors such as hepatitis, 
human immunodeficiency virus and many other difficult to detect 
viral diseases. These obstacles limit application of this useful protein. 
Recent developments in biotechnology have allowed production 
of recombinant hLF (rhLF) using transformed mammalian cells in 
culture and by transformed bacteria in fermentation [27-29]. However, 
the yields have been low and since hLF is a highly folded, cross-linked 
and glycosylated protein, there has not been good success. A recent 
publication demonstrated successful production of rhLF in transgenic 
mice with production targeted to the mammary gland [30,31]. A 
previous attempt to produce rhLF in rice has so far not been fully 
successful as the plant glycosylation system modifies added asparagine 
linked glycans differently than mammalian cells and regulators of 
GMO’s (Genetically Modified Organism’s) have not approved the GM 
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(Genetically Modified) rice as acceptable. Together the data suggested 
that utilization of transgenic expression of rhLF in bovine mammary 
glands might provide an efficient mechanism for industrial scale 
production of hLF. 
Investigators at China Agricultural University produced two 
transgenic cows, one that secreted rhLF at 2.5 g/L and a second that 
secreted rhLF at 3.4 g/L in their milk. Transformation was accomplished 
through microinjection of a bacterial artificial chromosome (BAC) 
containing a copy of genomic clone (~150 kb) of hLF into bovine 
fibroblasts, followed by somatic cell cloning and transfer to the uterus of 
recipient cows with a small number of transgenic calves being produced 
[32]. In previous studies of the rhLF transgenic cows the composition 
of milk and milk powder from transgenic cows were compared to 
that from non-transgenic cows. The results did not demonstrate any 
significant differences with the exception of the presence of high levels 
of rhLF in the transgenic milk [32,33]. Biochemical characterization 
of rhLF and hLF demonstrated slight differences in molecular weight, 
with rhLF being slighly lower than hLF. The difference may be due to 
small variations in glycosylation profiles between the two proteins. 
Detailed characterization of glycosylation patterns of rhLF expressed 
in bovine mammary glands demonstrated diverse structures [34]. The 
results indicated that hLF and rhLF were glycosylated at the same two 
sites: Asn138 and Asn479. The differences between rhLF and hLF in 
N-glycosylation profiles were consistent with the widely held view 
that glycosylation is species- and tissue/cell- specific [34]. Importantly, 
neither glycan structures (fucose and xylose substitutions at specific 
sites) that are known to be responsible for irrelevant IgE binding in 
some subjects [35] nor alpha-galactose that has been demonstrated to 
cause adverse immunological reactions [36] was detected on rhLF [37].
The susceptibility to proteolysis of rhLF was studied and compared 
with that of natural hLF [32]. Results of the in vitro tests indicated that 
pepsin can digest rhLF completely in 60 min, which was similar to that 
of natural hLF. 
Finally, the in vitro antibacterial effect of rhLF, iron binding and 
releasing properties was researched and the comparison was conducted 
between rhLF and hLF. The results also demonstrated that rhLF’s 
properties are similar to hLF [32]. 
As a transgenic protein, it is necessary to evaluate the allergeinicity 
of rhLF expressed in GM cows according to international standard. 
In this study a bioinformatics analysis, tests of the stability of rhLF in 
pepsin and the serum reactivity tests were conducted to evaluate rhLF’s 
potential allergenicity. An important under-stated consideration in the 
Codex guidelines and various country regulations is the history of safe 
use [38,39]. Since hLF is produced in secretory glands of the human 
body including mammary, lacrimal and salivary glands as well as in 
polymorphonuclear leukocytes, human exposure to the protein is not 
only common, but constant. There are no reports of allergy to this self-
protein. Thus the likelihood of allergy to an exogenous source of the 
protein, if it has the same amino acid sequence is negligible. 
Materials and Methods
Bioinformatics analysis
On the basis of the recognized international guidelines for evaluating 
GMO’s the allergenicity of rhLF expressed in the milk of transgenic 
cow was evaluated simply based on bioinformatics and resistance to 
digestion by pepsin. The amino acid sequence comparison for rhLF was 
conducted with three databases; FARRP (http://www.allergenonline.
com), SDAP (http://fermi.utmb.edu/SDAP/sdap_src.html) and ADFS 
(http://allergen.nihs.go.jp/ADFS/), which are widely used in the world 
at present [40-42]. The primary methods of evaluation were searches for 
“80 amino acid alignments with greater than 35% identity by FASTA” 
and “8 amino acid exact matches”. Because of the peptide match of 6 
continuous amino acids to known allergens will result in many false 
positives [41,42] and produce many random, irrelevant matches [43], 
this method was not used in this evaluation. 
Stability to pepsin digestion 
The digestion resistance of rhLF was tested according to published 
methods [44]. Stimulated gastric fluid (SGF) was prepared to include 
pepsin purchased from Sigma Chemical (Shanghai, Sigma-Aldrich 
China, Inc), with a stated activity of 4220 U/mg of protein as analyzed 
by Sigma. In this study a ratio of 20 U of pepsin activity/µg of test 
protein, about 5:1 (w/w), was used throughout the study. The other 
materials, bovine serum albumin (BSA) and bovine β-lactoglobulin 
(BLG) were also obtained from Shanghai, Sigma-Aldrich China, Inc. 
for use as control proteins. It has been reported that the BSA is labile 
and the BLG is stable to SGF in standard condition [44]. Samples of 
digestion products were evaluated in SDS-PAGE with gel staining 
according to standard conditions. Images of stained gels were captured 
and compared using a gel imaging instrument (GelDoc-It Imaging 
System, P/N 95-0441-02, USA). 
Human serum test
The results of amino acid sequence comparison showed that rhLF 
shares 71.4% identity with bLF and 52.2% identity with ovotransferrin, 
two reported allergens [45-48]. As the serum screen is recommended 
in some guidelines, human serum tests with rhLF were conducted to 
further evaluate the potential allergenicity of rhLF using sera from 
donors allergic to milk or egg. 
Sera of consenting donors were collected under institutional review 
board approval from 12 egg-allergic subjects and 21 milk-allergic 
individuals for use in this study. The donors were diagnosed as allergic 
to egg or milk based on clinical histories, skin prick test (SPT) and 
specific IgE tests (allergic specific Pharmacia UniCAP tests). The level 
of egg- or milk- specific IgE in all of the sera samples were >3.5 KUA/L. 
Additionally, serum samples from individuals were mixed as serum 
pool to be used as negtive control. 
Immunoblots were conducted according to the previous protocol 
[49-51] with some modifications. In brief, the SDS-PAGE was 
conducted using 400 ng purified rhLF, bLF, hLF (kindly provided by 
professor Li Ning, Purity: 98%) and 10 μg protein extract prepared 
from a standard egg powder (Lot. 1452807v, USA) or from milk 
powder (NO. 1549, USA.) with samples loaded in adjacent wells of 
the gel. Following separation of proteins by electrophoresis, proteins 
were either stained with Coomassie blue or transferred to nitrocellulose 
membranes (NC) for immunoblot. Membranes were then rinsed with 
distilled water and blocked by submersion in 3% BSA in PBS buffer for 
2 h at room temperature. After washing, the blocked membranes were 
incubated 2 h at room temperature in individual allergic sera or control 
sera, which had been diluted 1:20 (v/v) in blocking buffer 30 min prior 
to adding to the membrane. The membranes were washed 6 times in 
TBST (0.02M, 0.05% Tween-20), then incubated for 1 h in monoclonal 
mouse anti- human IgE conjugated with horseradish peroxidase (HRP) 
(kindly provided by professor Li Ning) that was dilluted 1:8000 (v/v) 
in blocking solution. After 6 washes in TBST solution, detection was 
achieved using ECL (enhanced chemiluminescence; Amersham 
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BioSciences, Piscataway, NJ; No. RPN2106), with exposure for 3 min 
on the X-ray films. 
Results 
Bioinformatics comparison 
Results of the overall FASTA alignment demonstrated that 
rhLF shares 71.4% identity to bovine lactoferrin (bLF), 52.2% to 
ovotransferrin and 51.9% to ovotransferrin precursor, using the FARRP 
allergen database (Figure 1). Additionally the results of “80 amino acid 
alignments” showed the sequence of rhLF contains 532 sliding 80 amino 
acid alignments hit >35% to bLF or ovotransferrin or ovotransferrin 
precursor using the sliding window search on the FARRP website 
(Figure 1). 
Pepsin stability of rhLF
The results if digestion experiments are shown in figure 2. The 
samples of BSA were digested completely in SGF in 15 s and BLG 
samples were still clearly visible after 60 min digestion by pepsin. The 
rhLF was digested in 15 s by pepsin as found in a previous study [32]. 
Human serum tests
The results of Bioinformatics comparison suggested rhLF might act 
as a cross-reactive allergen for some consumers allergic to bovine milk 
or hen’s eggs and based on guideline recommendations, human serum 
testing should be performed. However, since hLF is widely expressed 
in every human, and there are no data to support subjects allergic to 
human lactoferrin, there is no risk and there should not be a need to 
perform serum tests. In order to satisfy regulatory requirements and in 
anticipation of questions from consumers or regulators, a decision was 
made to test serum IgE binding. 
As shown in figure 3, after SDS-PAGE and stained with coomassie 
brilliant blue, there are mainly 4 protein bands, which are about 65 
KD (Bovine Serum Albumin, BSA), 34 KD, 26 KD (Caseins, CAS) 
and 18 KD (β-lactoglobulin, LG) in the extraction of standard milk 
powder. 10 protein bands were evident in the egg powder and their 
molecular weight were approximately 230 KD, 150 KD, 130 KD, 83 KD 
(Ovotransferrin, OVT), 72 KD, 60 KD, 45 KD (Ovalbumin, OVA), 40 
KD, 34 KD, 28 KD (Ovomucoid, OVM). Since the standard egg powder 
used in this study was whole egg powder, it is assumed that the high 
weight molecules are from the yolk. The three obvious banding in lane 
3, 4 and 5 were rhLF, hLF and bLF respectively, and their MW were all 
about 80 KD. 
The immunoblot results are shown in figure 4, there was no visible 
binding band in the membrane that incubated with control serum 
from healthy donors (Figure 4B). The notable IgE binding reaction was 
detected in the protein bands of 150 KD, 83 KD, 45 KD, 34 KD in egg 
powder and of 65 KD, 26 KD, 18 KD in milk powder. These proteins 
maybe the important allergens, which named as ovotransferrin (OVT), 
ovabumin (OVA), ovomucoid (OVM), bovine serum albumin (BSA), 
casein (CAS) and lactoglobulin (LG) in egg and milk (Figures 4C and 
4D). This is in accordance to previous study [52]. And finally, there was 
no visible IgE binding reaction to purified rhLF, hLF and bLF in all of 
the test serum samples (Figures 4C and 4D). Because of the sensitivity 
of this immunoblot and detection method which used ECL, IgE should 
be detectable at the level of pg and the banding reaction of protein and 
its antibody was detected in our preliminary experiment when the 
loaded dose was 40 ng (Figure 4A). So the lack of apparent IgE binding 
to hLF and rhLF demonstrates that there would not be any IgE binding 
to the rhLF expressed in cow’s milk.  
Discussion 
As one of functional proteins that is secreted by multiple tissues of the 
human body, hLF is always present in various organs and fluids (blood, 
lymph, milk, saliva, semen, and tears) of humans. Dietary exposure is 
common for infants who are breast fed as well as continuing exposure 
through saliva and bile. Exposure to lactoferrin certainly starts before 
birth. However, no evidence of allergy to human lactoferrin has been 
reported. It’s common and high expression level in various fluids and 
in PMNs is expected to lead to immune tolerance rather than allergy 
or other adverse immune responses to self [53]. Immune tolerance is 
primarily formed in the embryonic period and soon after birth when 
the immature T lymphocyte and B lymphocyte contact the self-protein 
or the other substance and this can be maintained throughout life. 
In previous studies it was demonstrated that the rhLF expressed in 
the milk produced from transgenic cows has similar in antimicrobial, 
iron binding and growth promoting activity of epithelial cells [32]. 
An earlier study of the glycosylation patterns of rhLF were compared 
to natural hLF [34]. The Cross-reactive Carbohydrate Determinant 
(CCD) type glycans (xylose or fucose substituted complex N-linked 
glycans) and alpha-gal are often considered as potential allergenic 
carbohydrates in protein [54-56]. The results show that only a small 
amount of Neu5Gc was detected by HPLC and no other antigenic 
carbohydrates were found [34]. And the glycosylation profile of rhLF 
was similar to hLF. 
In recent years, a number of international organizations, including 
the Food and Agricultural Organization (FAO) and World Health 
Organization (WHO) and Codex Alimentarius Commission (CAC) 
developed recommendations for the evaluation of GMO’s for potential 
allergenicity in foods. The International Food Biotechnology Council 
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The amino acid sequence of rhLF is GRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYG-
TERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYF-
SYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQ-
KDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAG-
KCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLAVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDE-
QGENKCVPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQA
KFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
Figure 1: Results of bioinformatics analysis of hLF. It was compared to allergens contained in the FARRP allergen database, version 11.
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and the Allergy and Immunology Institute of the International Life 
Sciences Institute (IFBC/ILSI) presented a decision-tree approach 
to evaluate the potential allergenicity of the exogenous proteins in 
genetically modified crops intended for food use [37] in 1996. If the 
source of the gene (donor) is known to cause allergies, serum from a 
number of individuals allergic to the donor would be used to test for 
IgE binding to the protein encoded by the transferred gene. The amino 
acid sequence would also be compared to those of known allergenic 
proteins and if any eight amino acid segment was identical to a segment 
of an allergen, serum from a number of subjects allergic to the source 
of the allergenic protein would be used in similar tests. The stability of 
the protein would also be tested in pepsin under standard conditions of 
fixed concentrations at pH 1.2 as a number of important food allergens 
were known to be stable in pepsin. The abundance of the protein and 
stability (of function) of the protein under heated conditions would also 
be considered as secondary additional characteristics of possible risk of 
allergy. This approach [37] was accepted by scientific panels organized 
by the FAO/WHO in 1996 and 2000 during joint Consultations on the 
safety assessment of genetically modified foods of plant origin. During 
an additional consultation of scientists, the FAO/WHO 2001 suggested 
a modified decision tree that changed criteria and broadened some 
of the previous approaches [57]. For sequence comparisons identity 
matches of >35% over any segment of 80 or more amino acids or any 
100% identity match of six or more contiguous amino acids significant 
would trigger specific IgE testing using sera from individuals allergic 
to the source of the matched allergen. In addition, targeted serum 
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Figure 2: Result of three proteins digested in a standard in vitro pepsin 
digestion assay. The stained gel images show that BSA was rapidly digested, 
while BLG was relatively resistant to SGF. The rhLF test protein was digested 
in less than 15 s.
Figure 3: SDS-PAGE of standard egg powder and milk powder extracts. Lane 
1: standard milk powder extracts (10 μg); Lane 2: standard egg powder extract 
(10 μg); Lane 3: recombinant human lactoferrin (rhLF, 400 ng); Lane 4: human 
lactoferrin (hLF, 400 ng); Lane 5: bovine lactoferrin (bLF, 400 ng); Lane 6: 
molecular weight marker (the standard weight band is 170 KD, 130 KD, 95 KD, 
72 KD, 55 KD, 43 KD, 34 KD, 26 KD and 10 KD respectively). The rhLF, hLF 
and bLF were detected in the gel at a loaded dose of 400 ng.
Figure 4: Results of representative IgE Immunoblots from samples of 
standard egg and milk. Picture A was the positive control of rhLF and hLF 
using specific antibody to rhLF and hLF. The order of the laoded samples in 
picture A were Lane 1: recombinant human lactoferrin (rhLF, 40 ng), Lane 
2: human lactoferrin (hLF, 40 ng), Lane 3: ddH2O (15 µl). The order of the 
laoded samples in the picture B was as Lane 1: standard milk powder extracts 
(10 μg), Lane 2: standard egg powder extracts (10 μg), Lane 3: recombinant 
human lactoferrin (rhLF, 40 ng), Lane 4: human lactoferrin (hLF, 40 ng), Lane 
5: bovine lactoferrin (bLF, 40 ng). The serum used in picture B to incubate the 
membrane was mixture of 5 control sera. In picture C and D, Lane 1: standard 
egg powder extracts in C (10 μg) or standard milk powder extracts in D (10 μg), 
Lane 2: recombinant human lactoferrin (rhLF, 40 ng), Lane 3: human lactoferrin 
(hLF, 40 ng), Lane 4: bovine lactoferrin (bLF, 40 ng). The C was obtained by 
incubating the memnrane with a pool contained 12 sera from individual donors 
allergic to egg. The level of egg specific IgE in all of the 12 sera samples were 
>3.5 KUA/L. Finally, 21 sera donated from individual donors allergic to milk 
were mixed to incubate the membrane D, and the level of milk specific IgE in 
the serum was also >3.5 KUA/L. In egg and milk there were sevral proteins 
binded to specific allergic serum, while the rhLF, hLF and bLF. This indecate 
that there was not cross reaction between rhLF and egg, milk. 
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testing was suggested, where up to 50 individual donors allergic to 
broad taxonomic categories would be tested (e.g. those allergic to foods 
or pollen of various monocotyledons would be used if the gene was 
from any monocot). However, targeted screening would not be used if 
the gene was from a bacterium. Stability to digestion of the protein in 
pepsin would also be tested, but the using of two pH conditions (1.2 
and 2.0) was recommended. The final recommendation was to attempt 
to sensitize two species of animals, or one species, but use two routes of 
exposure to evaluate the sensitizing potential of the purified GM protein. 
The Codex Alimentarius Commission reviewed the FAO/WHO 2001 
guidelines among other recommendations and indicated that animal 
models have not been proven to be predictive, that the bioinformatics 
criteria of >35% identity in 80 amino acid overlap by FASTA would be 
considered positive, that any short amino acid identity matches should 
be scientifically justified and that pepsin digestion could be performed 
at pH 1.2 or 2.0 [58]. The Codex Alimentarius Commission did not 
recommend using targeted serum testing, but only specific testing to 
evaluate proteins expressed by genes taken from allergenic sources 
or proteins exceeding the bioinformatics criteria (above) [58,59]. 
Regulatory agencies in many countries including Canada, Australia 
and New Zealand, Japan, South Korea, Taiwan and the U.S. follow 
the Codex guidelines. The European Food Safety Authority (EFSA) 
[60] has developed slightly more explicit guidelines that are intended 
to be followed by members of the European Union [61]. The issue of 
heat stability has not been clearly demonstrated as predictive for food 
allergy as the relationship only appears to be useful for predicting risk 
if the unheated protein binds IgE or causes allergic reactions, but the 
recombinant protein expressing in a food source is always heated [62]. 
Then testing stability of IgE binding or elicitation of allergic reactions 
with heated protein should be used in risk assessment. 
In China, the Ministry of Agricultural set the “Transgenic plant safety 
evaluation guidelines” to guide the application and safety evaluation 
of transgenic plant [63], and as reference of the safety assessment 
of transgenic animals. In this guideline, the data of bioinformatics, 
stimulation gastric stability was necessary in the allergenic evaluation. 
In addition, an interpretation of many guidelines to require human 
serum tests using sera from individuals allergic to milk due to matches 
to bovine lactoferrin, or to egg due to matches to ovotransferrin as 
described in this research.
As discussed above, several methods containing bioinformatics 
analysis, stability to pepsin and serum tests were used to research the 
rhLF’s allergenicity.
Conclusion 
Based on the results of an evaluation process that follows Codex 
guidelines and considers history of safe use, there is no evidence to 
suggest that rhLF as expressed in transgenic cows, would pose a risk of 
allergy to consumers. So it may be added into food or formula powder 
to improve their nutrition condition. 
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